A leading expert in hematology-oncology, Dr. Thomas Martin is associate director of UCSF's myeloma program and director of the unrelated donor transplantation programs for adults at UCSF Medical Center.

Martin is clinical research director of hematologic malignancies (blood cancers) at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants, and he is involved in efforts to improve outcomes for patients who have transplants from unrelated donors.

Martin earned an undergraduate degree at Cornell University and his medical degree at the University of Connecticut School of Medicine. After a medical residency at Harbor-UCLA Medical Center, he completed a fellowship in hematology-oncology at UCSF. In 1999, he joined MD Anderson Cancer Center as an assistant professor of medicine. In 2001, he returned to UCSF.

  • Education

    University of Connecticut, School of Medicine, 1989

  • Residencies

    Harbor-UCLA Medical Center, Internal Medicine, 1992

  • Fellowships

    UCSF Hematology/Oncology Division, Hematology/Oncology, 1996

  • Board Certifications

    Hematology, American Board of Internal Medicine

  • Academic Title


  • Languages


Where I see patients (2)

    My reviews


    Overall Experience
    311 Ratings
    Explained things in a way that was easy to understand
    310 Ratings
    Did the doctor pay attention to your concerns
    309 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    308 Ratings
    Knew the important information about your medical history
    310 Ratings
    The provider showed respect for what you had to say
    309 Ratings
    The provider spent enough time with me
    310 Ratings

    Selected research

    Decorative Caduceus

    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (C...

    The primary objective of this access and distribution protocol is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not FDA licensed.


    Decorative Caduceus

    Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refrac...

    Treatment-related Adverse events resulting in a DLT will be summarized by maximum toxicity grade for each dose level of isatuximab.


    Decorative Caduceus

    A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection ...

    The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.


    Decorative Caduceus

    Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma

    The per-patient incidence of Grade 2 or higher IRRs with rapid infusion (RI) isatuximab will be calculated as the number of patients who developed >= 1 Grade 2+ IRR with RI isatuximab divided by the total number of patients who re...